iCRAS

Executive Summary

iCRAS Inc. (San Diego, CA) provides specialized clinical research auditing services, including GxP/GCP audits, CAPA training, SOP development, and FDA inspection readiness for biopharma sponsors and CROs. Founded in 2018, the company operates in the clinical quality assurance niche, addressing the increasing regulatory complexity in drug development. While categorized under AI/Machine Learning and Drug Delivery, its core offering is service-based rather than product-driven. iCRAS likely benefits from the growing volume of clinical trials and heightened FDA scrutiny, but as a private entity with no disclosed funding or revenue, its financial trajectory is opaque. The company's focus on compliance and inspection support positions it as a steady partner for clinical research organizations seeking to mitigate regulatory risks.

Upcoming Catalysts (preview)

• Q4 2026Preferred Provider Agreement with a Major Biopharma or CRO65% success
• Q3 2026Launch of AI-driven Audit Analytics Platform55% success
• Q1 2027Expansion into European Clinical Audit Services50% success